Stallergenes Greer is a global biopharmaceutical company specialising in the diagnosis and treatment of respiratory, food allergies and venoms through the research, development and commercialisation of allergen immunotherapy products and services. Our purpose is to enable precision medicine to improve life for people with allergies. With nearly 1,100 employees worldwide, a presence in 44 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer International AG is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing leadership in allergy immunotherapy. Link to our privacy policy: https://www.stallergenesgreer.com/personal-data-protection-policy

Website: https://www.stallergenesgreer.com

Employees: 1070

HQ: +44 20 7239 4500

Location: London, N/A, UK

Revenue: $290.3 million

Stallergenes Greer is a global biopharmaceutical company that specializes in the diagnosis and treatment of respiratory allergies. With a focus on precision medicine, the company aims to improve the lives of people with allergies. Stallergenes Greer has a strong presence in 40 countries and operates manufacturing facilities in both Europe and the United States. The company's product portfolio includes Allergy Immunotherapy products and services, which are designed to provide effective and long-lasting relief for patients. Stallergenes Greer's leadership team boasts a wealth of experience and expertise in the industry. Fereydoun Firouz serves as the Chairman and CEO, while Emily Duff holds the position of Director | Office of the CEO. Daniel Smith serves as the Global Head of Information Technology, and Sarah Khan is the Executive Assistant to the Chief Executive Officer. Michele Antonelli is the CEO and Board Member of the company. The company's commitment to innovation and patient care has earned it a reputation as a leader in the field of allergy immunotherapy. Stallergenes Greer's dedication to improving the lives of people with allergies is evident in its mission to enable precision medicine. With a strong focus on research and development, the company continues to drive progress in the industry. In conclusion, Stallergenes Greer is a global biopharmaceutical company that is dedicated to improving the lives of people with allergies. With a strong leadership team and a focus on innovation, the company is well-positioned to continue driving progress in the field of allergy immunotherapy.

Stallergenes Greer is a global company that helps people with respiratory allergies. They develop and sell products and services to diagnose and treat allergies. Their goal is to improve life for people with allergies by using precision medicine. They have over 1,100 employees worldwide and are present in 40 countries. They have manufacturing facilities in both Europe and the United States. Stallergenes Greer is the parent company of GREER Laboratories, Inc. and Stallergenes S.A.S. They work together to be a leader in allergy immunotherapy.